Diagnosis and treatment of multiple sclerosis

Acta Neurologica Scandinavica

Volumn 117, Issue SUPPL. 188, 2008, Pages 12-21

  Myhr, Kjell Morten ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Diagnosis; Multiple sclerosis; Treatment

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BG 0012; CLADRIBINE; DACLIZUMAB; DEXAMETHASONE; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISOLONE; RITUXIMAB; TERIFLUNOMIDE; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ANAPHYLAXIS; ANXIETY; BACKACHE; BRAIN DAMAGE; CARDIOTOXICITY; CEREBROSPINAL FLUID; CHEST TIGHTNESS; CHILL; CLINICAL EVALUATION; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; DYSPNEA; ERYTHEMA; EUPHORIA; EVOKED VISUAL RESPONSE; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; HAIR LOSS; HEADACHE; HEART PALPITATION; HUMAN; INJECTION PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INSOMNIA; LEUKEMIA; LEUKOPENIA; LIPOATROPHY; LIVER FAILURE; LOW DRUG DOSE; LYMPHADENOPATHY; MENSTRUATION DISORDER; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PANCREATITIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REMISSION; REVIEW; SIDE EFFECT; SPINAL CORD LESION; TASTE DISORDER; TREATMENT FAILURE; URINARY TRACT INFECTION; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 42649133473     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01026.x     Document Type: Review

References (59)

1. Myhr KM, Riise T, Vedeler C et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001 7: 59 65.
2. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006 5: 343 54.
3. Bö L, Geurts JJ, Mörk SJ, Van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 2006 183: 48 50.
4. Torkildsen Ø, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurol Scand Suppl 2007 187: 46 50.
5. Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001 50: 121 7.
6. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 58: 840 6.
7. Barkhof F, Filippi M, Miller DH et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997 120: 2059 69.
8. Tintoré M, Rovira A, Martinez MJ et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000 21: 702 6.
9. Miller DH, Rudge P, Johnson G et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988 111: 927 39.
10. Andersson M, Alvarez-Cermeño J, Bernardi G et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994 57: 897 902.
11. Thompson AJ, Montalban X, Barkhof F et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000 47: 831 5.
12. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003 126: 770 82.
13. Sellebjerg F, Barnes D, Filippini G et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005 12: 939 46.
14. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998 51: 529 34.
15. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: a profile of adverse events. J Neurol Neurosurg Psychiatry 1988 51: 285 7.
16. Weinshenker BG, O'brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Neurology 1999 46: 878 86.
17. Yong WV, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998 51: 682 9.
18. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 45: 1277 85.
19. Jacobs LD, Cookfair DL, Rudick RA et al. Multiple Sclerosis Collaborative Research Group (Mscrg). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 39: 285 94.
20. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352: 1498 504.
21. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999 46: 197 206.
22. Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 2000 22: 149 59.
23. Frohman EM, Brannon K, Alexander S et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 2004 10: 302 7.
24. Montero JL, Cerezo A, Fraga E et al. Acute liver failure in a patient with multiple sclerosis treated with interferon-beta. Mult Scler 2000 13: 820.
25. Midgard R, Ag KE, Trondsen E, Spigset O. Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis. Neurology 2005 65: 170 1.
26. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 343: 898 904.
27. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 357: 1576 82.
28. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 67: 1242 9.
29. Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 370: 389 97.
30. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 46: 907 11.
31. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352: 1491 7.
32. Panitch H, Miller A, Paty D et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 63: 1788 95.
33. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001 56: 1496 504.
34. Cohen JA, Cutter GR, Fischer JS et al. Impact Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002 59: 679 87.
35. Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004 10 (Suppl 1 S46 54.
36. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003 60: 44 51.
37. Sørensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 12: 817 27.
38. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007 4: 647 53.
39. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 45: 1268 76.
40. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001 49: 290 7.
41. Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 50: 701 8.
42. Wolinsky JS, Narayana PA, O'connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007 61: 14 24.
43. Polman CH, O'connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354: 899 910.
44. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 354: 924 33.
45. Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 6: 431 41.
46. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 69: 1391 403.
47. Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2006 109: 198 209.
48. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997 62: 112 18.
49. Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997 244: 153 9.
50. Hartung HP, Gonsette R, König N et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet 2002 360: 2018 25.
51. Karussis D, Biermann LD, Bohlega S et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006 13: 61 71.
52. Freedman MS, Patry DG, Grand'maison F et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004 31: 157 68.
53. Panitch H, Goodin DS, Francis G, et al. Evidence Study Group. Evidence of interferon dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 59: 1496 506.
54. Durelli L, Verdun E, Barbero P et al. Independent Comparison Of Interferon (Incomin) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 359: 1453 60.
55. Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics 2007 4: 633 46.
56. Wolansky L, Cook S, Skurnick J et al. Betaseron vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome. ECTRIMS 2007, late breaking news; http://www.akm.ch/ ectrims2007.
57. Mikol DD, Barkhof F, Chang P et al. The REGARD trial: a randomised assessor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. ECTRIMS 2007, late breaking news; http://www.akm.ch/ectrims2007.
58. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007 61: 1922 30.
59. Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics 2007 4: 676 92.